SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as the community anticipates the launch of a new ETF, sparking discussions about potential institutional investment and increased exposure for HBAR. Community members are actively debating price targets and potential 'sell the news' scenarios, while highlighting Hedera's real-world adoption and strong network growth. Some investors express concerns about past performance and token unlocks.

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

TPST is trending amid ongoing speculation of a potential acquisition, with community members highlighting its promising oncology assets and Roche's potential interest. Discussions revolve around Roche's existing collaboration with Tempest and the strategic value of acquiring TPST's liver cancer therapy. Some traders express concerns about cash runway and timing, while others point to technical indicators and potential buyout scenarios, anticipating news soon.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the company's L- and S-band frequencies are now part of the official global 3GPP standard, potentially enabling direct-to-device satellite connectivity on billions of existing phones; the community is discussing the significance of this standardization and its impact on scalability and partnerships with mobile network operators. Bullish sentiment surrounds the implications of this milestone, with some speculating about future partnerships and government contracts, while bears express concerns about dilution and valuation.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following news of its acquisition of Arduino, a move seen as expanding its reach in AI and robotics. The community is discussing the potential benefits of this acquisition and how it may position the company against competitors. Some traders are closely watching technical indicators and option flow for potential upside.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica ($CLS) is trending due to strong reactions to earnings, which included a beat and increased guidance, fueling bullish sentiment. The community highlights the company's exposure to the growing data center market and some are comparing its potential to that of $NVDA. Discussions also include possible price targets, long-term growth prospects, and the impact of technical factors.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF ($DAX) is trending as analysts discuss its bullish momentum and potential for further gains, particularly noting the strong buying opportunity around the "Blue Box" area. Community discussions revolve around Elliott Wave analysis, identifying key support levels and potential paths for continued upside. Broader market commentary suggests a positive outlook for European equities, with some analysts pointing to potential outperformance compared to U.S. markets.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

BIDU is trending as investors discuss its AI potential, particularly the expansion of its robotaxi service and recent Cathie Wood purchases. Community members are weighing positive catalysts against bearish sentiment and potential profit-taking. Broader discussions involve comparing valuations and growth prospects within the Chinese tech sector.

Perimeter Solutions, Inc. engages in the provision of global solutions for fire safety and specialty products industries. It operates through the Fire Safety and Specialty Products segments. The Fire Safety segment specializes in the formulation, manufacture, and sale of fire retardants and firefighting foams that assist in combating various types of fires, including wildland, structural, flammable liquids, and others. It also offers specialized equipment and services, which include airbase retardant storage, mixing, and delivery equipment, mobile retardant bases, retardant ground application units, mobile foam equipment, and others The Specialty Products segment produces and sells phosphorus pentasulfide (P2S5), primarily used in the preparation of lubricant additives, including a family of compounds called zinc dialkyldithiophosphates (ZDDP) that provide critical anti-wear protection to engine components. The company was founded in 2018 and is headquartered in Clayton, MO.

Perimeter Solutions Inc.

Perimeter Solutions SA

Perimeter Solutions ($PRM) is trending due to a recent USDA agreement and positive analyst ratings, with UBS maintaining a Buy rating and raising the price target. The community is discussing the company's strong financials, potential for long-term growth in fire safety products, and a possible monopoly on USDA-quality fire retardant. Some traders are noting bullish sweep call activity and anticipating upcoming earnings.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors discuss its potential amid mixed sentiment, influenced by a recent analyst downgrade and news of layoffs. Despite concerns about EV demand and cash burn, the community is also focused on the company's long-term prospects, including the upcoming R2 vehicle and its relationship with Amazon. Technical analysis suggests a possible breakout, with some traders eyeing potential upside based on future production and profitability.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending ahead of its Q3 earnings report, with investors anticipating strong double-digit growth and debating whether positive results are already priced in. The community is actively discussing potential price movements, including a possible post-earnings sell-off, as well as the potential for SoFi to be added to the S&P 500. Bullish sentiment remains strong among long-term holders, who see a bright future for the fintech company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RedHill Biopharma Receives Nasdaq Staff Determination Notification

RedHill Biopharma Receives Nasdaq Staff Determination Notification RedHill Biopharma Receives Nasdaq Staff Determination Notification PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Oct. 22, 2025 On...

RedHill Biopharma’s&nbsp;stock recorded its best trading session in more than a year on Monday after the New York Supreme Court upheld a $10 million award in the company’s ongoing legal dispute with Kukbo.Shares of the company jumped 27.2%, to close at $2.34 on Monday, before slipping 7.1% to $2.17 in after-hours trading.The Court reaffirmed its original summary judgment ruling in favor of RedHill, dismissing Kukbo’s appeal and the entirety of its defense. It ruled that Kukbo breached both the subscription and exclusive license agreements signed with RedHill in 2021 and 2022 and that RedHill had properly fulfilled its obligations, even after Kukbo’s non-payment.The total award amounts to approximately $10 million,&nbsp;comprising the original judgment of $8.25 million and an additional $1.82 million granted in August 2025 for legal costs and expenses. Both awards carry a 9% ongoing statutory interest accrual. Kukbo retains the right to further appeal the ruling.In addition to the U.S. court ruling, RedHill also secured a court-ordered seizure of Kukbo’s assets in May 2025 from Korea’s Incheon District Court, freezing those assets following the initial $8.25 million award and preventing their disposal before judgment enforcement. In August, RedHill received an additional $1.82 million for legal expenses.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 9,900% surge in 24-hour message volume.One user stated that short sellers were likely to get squeezed, arguing that RedHill’s market capitalization of approximately $7 million was significantly below the $10 million court award and calling the stock undervalued, with a fair price between $5 and $7.<stembedurl>https://stocktwits.com/PeterTauscher/message/630386393</stembedurl>Another user reported an increase in their position, noting that several potential catalysts could drive the stock higher in the coming months.<stembedurl>https://stocktwits.com/Imatron12/message/630390832</stembedurl><a href="https://stocktwits.com/symbol/RDHL">RedHill Biopharma’s stock</a> has declined 62.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RedHill Biopharma’s stock (RDHL) has declined 62.3% so far in 2025. (Photo credit: Getty Images)

RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead

The stock rallied after the New York Supreme Court reaffirmed RedHill’s $10 million award in its dispute with Kukbo.

Equity

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties RedHill Licenses RHB-102 for...

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate...

RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published RedHill's Talicia Adds 8 Million Lives...

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development Radioprotective Activity of RedHill's...

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court...

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry...

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND PR Newswire...

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury RedHill Announces Collaboration with a Leading...

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Redhill Biopharma Ltd. - ADR

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.57
Prev Close	$1.64
Open	$1.67
Dividend Yield	0.00%
50-Day Moving Average	$1.63
Beta	0.80
Avg. Volume	2.73M
PE Ratio	-0.02

52-Week High	$8.75
52-Week Low	$1.06
Market Capitalization	$5.46M
EPS (Annual)	-$6.73
Price to Book	-0.82
Revenue Per Employee	$230,890.69
Enterprise Value/EBITDA	N/A

RDHL
RedHill Biopharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest RDHL News

RDHLRedHill Biopharma Ltd.